Di-Methyl-Histone H3 (Lys9) Antibody

What is Di-Methyl-Histone H3 (Lys9) and why is it significant in chromatin biology?

Di-methylation of histone H3 at lysine 9 (H3K9me2) is a critical epigenetic modification associated with transcriptional repression. Histone H3 is one of the four core histones (H2A, H2B, H3, and H4) that make up the nucleosome core particle, the basic unit of chromatin . The methylation of H3K9 is catalyzed by specific histone methyltransferases such as SuvH39H1 or G9a and is strongly linked to gene silencing mechanisms . This modification serves as a recruitment platform for chromatin-modifying proteins containing methyl-lysine binding modules, which further promote chromatin condensation and repressive chromatin states .

What are the primary applications for Di-Methyl-Histone H3 (Lys9) antibodies in epigenetic research?

Di-Methyl-Histone H3 (Lys9) antibodies are versatile tools with multiple validated applications in epigenetic research:

These applications enable researchers to investigate the role of H3K9 dimethylation in diverse biological processes from development to disease .

How do I choose between polyclonal and monoclonal Di-Methyl-Histone H3 (Lys9) antibodies?

The choice between polyclonal and monoclonal antibodies depends on your experimental needs:

Polyclonal Antibodies:

• Recognize multiple epitopes around the H3K9me2 modification

• Often provide stronger signals in applications like Western blotting and ChIP

• May exhibit batch-to-batch variation requiring validation for each lot

• Examples include rabbit polyclonal antibodies from Bio-Rad (AHP3066) and Sigma-Aldrich (07-441)

Monoclonal Antibodies:

• Recognize a single epitope with high specificity

• Provide superior lot-to-lot consistency and reduced background

• Often preferred for applications requiring high specificity like ChIP-seq

• Examples include Cell Signaling's D85B4 XP® Rabbit mAb (#4658) and Proteintech's Mouse Monoclonal (68825-1-Ig)

For critical experiments requiring high reproducibility across multiple studies, monoclonal antibodies are generally preferred due to their consistent performance .

What controls should I include when using Di-Methyl-Histone H3 (Lys9) antibodies for ChIP experiments?

Proper controls are essential for ChIP experiments using H3K9me2 antibodies:

Essential Controls:

• Input DNA control: Unprecipitated chromatin sample (typically 1-10% of starting material)

• Negative control antibody: IgG from the same species as the H3K9me2 antibody

• Positive control locus: Known H3K9me2-enriched genomic region (e.g., heterochromatic regions)

• Negative control locus: Region known to lack H3K9me2 (e.g., actively transcribed housekeeping genes)

• Peptide competition: Pre-incubation of antibody with H3K9me2 peptide to demonstrate specificity

For ChIP-seq applications, Cell Signaling Technology recommends using 10 μl of antibody and 10 μg of chromatin (approximately 4 x 10^6 cells) per immunoprecipitation for optimal results . Including total H3 ChIP as a normalization control is also advisable to account for nucleosome density variations across the genome .

How can I optimize Western blot protocols for detecting Di-Methyl-Histone H3 (Lys9)?

Optimizing Western blot protocols for H3K9me2 detection requires attention to several key factors:

Sample Preparation:

• Use acid extraction methods to efficiently isolate histones from nuclear proteins

• Consider using HeLa acid extract as a positive control

• Note that many chromatin-bound proteins are not soluble in low salt nuclear extracts and may fractionate to the pellet; therefore, a High Salt/Sonication Protocol is recommended when preparing nuclear extracts

Protocol Optimization:

• Use freshly prepared samples to avoid degradation

• Load 10-20 μg of histone extract per lane

• Separate proteins on 15-18% SDS-PAGE gels to resolve the low molecular weight histones (~17 kDa)

• Transfer to PVDF membranes (preferred over nitrocellulose for small proteins)

• Block with 5% BSA instead of milk (milk contains casein which has similar molecular weight)

• Use antibody dilutions of 1:2,000-1:5,000 as recommended by manufacturers

• Visualize using enhanced chemiluminescence or fluorescent secondary antibodies

Proper sample preparation is particularly critical as nucleosomal histones may not be efficiently extracted using standard protein extraction protocols .

What specialized techniques are required for immunofluorescence detection of H3K9me2 in tissues and cells?

Immunofluorescence detection of H3K9me2 requires specific techniques to preserve nuclear architecture and accessibility:

Cell/Tissue Preparation:

• Fix samples with 4% paraformaldehyde for 10-15 minutes

• Permeabilize with 0.1-0.5% Triton X-100 for nuclear access

• Consider antigen retrieval (typically heat-mediated in citrate buffer) for tissue sections

• Use acid extraction or specialized nuclear extraction buffers for optimal histone accessibility

Staining Protocol:

• Block with 3-5% BSA and 0.1% Triton X-100

• Apply H3K9me2 antibody at 1:200-1:800 dilution and incubate overnight at 4°C

• Wash thoroughly (3-5 times) with PBS containing 0.1% Tween-20

• Apply fluorophore-conjugated secondary antibody

• Counterstain nuclei with DAPI

• Mount with anti-fade mounting medium

When performing co-staining with other nuclear markers, carefully select antibodies raised in different host species to avoid cross-reactivity .

How can Di-Methyl-Histone H3 (Lys9) antibodies be utilized in CUT&Tag and CUT&RUN assays for high-resolution epigenome mapping?

CUT&Tag and CUT&RUN represent cutting-edge technologies for high-resolution epigenome mapping that can be performed with significantly fewer cells than traditional ChIP-seq:

CUT&Tag Protocol with H3K9me2 Antibodies:

• Bind cells to Concanavalin A-coated magnetic beads

• Permeabilize cells with digitonin

• Incubate with H3K9me2 antibody at 1:50 dilution

• Add pA-Tn5 transposase fusion protein that binds to the antibody

• Activate transposase to simultaneously cleave and tag DNA

• Amplify tagged DNA fragments by PCR

• Sequence library on Illumina platform

CUT&RUN Protocol Adaptations:

• Similar to CUT&Tag but using pA-MNase instead of pA-Tn5

• Release cleaved fragments for purification and library preparation

• Validated with several H3K9me2 antibodies including Cell Signaling Technology's products

These methods provide higher signal-to-noise ratios compared to traditional ChIP-seq and require only 1,000-50,000 cells, making them suitable for rare cell populations or limited clinical samples .

What are the most effective strategies for distinguishing between H3K9me1, H3K9me2, and H3K9me3 in multiplexed epigenetic analyses?

Distinguishing between the different methylation states of H3K9 is challenging but critical for understanding their distinct biological functions:

Antibody Selection Strategies:

• Use highly specific antibodies validated by peptide array assays to confirm minimal cross-reactivity

• Some antibodies react with both H3K9me1 and H3K9me2 (such as Proteintech 80219-1-RR and 68825-1-Ig)

• Others are specific to only H3K9me2 (such as Cell Signaling #9753 and #4658)

Peptide Competition Assays:

• Pre-incubate antibodies with specific methylated peptides

• Perform parallel experiments with each antibody

• Verify specificity through signal ablation with matching peptides

Mass Spectrometry Validation:

• Use quantitative mass spectrometry as a gold standard

• Analyze immunoprecipitated histones to confirm modification state

• Employ targeted MS approaches for validation of antibody specificity

Sequential ChIP (Re-ChIP):

• Perform sequential immunoprecipitations with antibodies against different methylation states

• Analyze overlap and differences between datasets to determine co-occurrence

Manufacturers like Cell Signaling Technology validate their antibodies against multiple methylation states to ensure specificity, as demonstrated in their validation data for the Di-Methyl-Histone H3 (Lys9) (D85B4) XP® Rabbit mAb .

How do experimental conditions affect the specificity and sensitivity of Di-Methyl-Histone H3 (Lys9) antibody in various applications?

Several experimental factors can significantly influence antibody performance:

Fixation Effects:

• Over-fixation can mask epitopes and reduce antibody accessibility

• For ChIP, formaldehyde crosslinking time should be optimized (typically 10-15 minutes)

• For immunofluorescence, paraformaldehyde concentration and fixation duration affect signal intensity

Buffer Composition Impacts:

• High salt concentrations (>300mM NaCl) may reduce antibody binding affinity

• Detergent type and concentration affect nuclear membrane permeabilization efficiency

• Buffer pH affects epitope conformation and antibody binding kinetics

Temperature Considerations:

• Primary antibody incubation at 4°C overnight generally produces optimal results

• Room temperature incubations may increase background signal

• Multiple freeze-thaw cycles can reduce antibody activity (aliquoting is recommended)

Blocking Agent Selection:

• BSA is generally preferred over milk proteins for histone applications

• Some commercial blockers may contain peptides that cross-react with histone antibodies

A systematic optimization approach is recommended when establishing new protocols with Di-Methyl-Histone H3 (Lys9) antibodies in different experimental systems .

What are common sources of batch-to-batch variation in Di-Methyl-Histone H3 (Lys9) antibodies and how can they be addressed?

Batch-to-batch variation is a significant concern, particularly with polyclonal antibodies:

Common Variation Sources:

• Different animals used for antibody production

• Variations in immunization protocols or antigen preparation

• Changes in purification methods

• Different lot numbers of immunizing peptides

Mitigation Strategies:

• Validation testing: Perform side-by-side comparisons of new and old antibody lots

• Reference sample: Maintain a standard positive control sample to test each new lot

• Peptide arrays: Use peptide arrays to confirm specific reactivity profiles

• Documentation: Keep detailed records of antibody performance metrics

• Recombinant antibodies: Consider switching to recombinant antibodies for critical applications

Cell Signaling Technology offers recombinant versions of their Di-Methyl-Histone H3 (Lys9) antibodies, which provide superior lot-to-lot consistency due to animal-free manufacturing processes .

How can researchers troubleshoot weak or non-specific signals when using Di-Methyl-Histone H3 (Lys9) antibodies?

When facing weak or non-specific signals, consider these troubleshooting approaches:

For Weak Signals:

• Increase antibody concentration: Try reducing dilution ratio (e.g., from 1:1000 to 1:500)

• Optimize extraction: Ensure proper histone extraction with acid extraction protocols

• Extend incubation time: Increase primary antibody incubation to overnight at 4°C

• Enhance detection: Use signal amplification systems (e.g., biotin-streptavidin)

• Check sample quality: Verify integrity of histones with total H3 antibody

For Non-specific Signals:

• Increase blocking: Use 5% BSA instead of 3% or extend blocking time

• Add competitors: Include 0.1-0.2 μg/μl sheared salmon sperm DNA in blocking solution

• Adjust washing: Increase stringency with higher salt or detergent concentrations

• Pre-clear samples: Pre-incubate lysates with beads before adding antibody

• Peptide competition: Perform parallel experiments with specific blocking peptides

If problems persist, consider switching to a monoclonal antibody with higher specificity or a recombinant antibody with consistent performance characteristics .

What methods are available for validating the specificity of Di-Methyl-Histone H3 (Lys9) antibodies in novel experimental systems?

Validating antibody specificity in new experimental systems is crucial:

Gold Standard Validation Methods:

• Peptide competition assays: Pre-incubate antibody with immunizing peptide (1 μM is typically sufficient) to confirm signal abolishment

• Histone methyltransferase knockout/knockdown: Use genetic models lacking enzymes responsible for H3K9 dimethylation (e.g., G9a/GLP knockout)

• Mass spectrometry: Analyze immunoprecipitated samples to confirm modification state

• Cross-reactivity testing: Test against panels of modified histone peptides

• Dot blot arrays: Apply modified peptides to membranes to test antibody specificity

Application-Specific Validation:

• For ChIP: Compare enrichment at known H3K9me2-positive and negative loci

• For Western blotting: Verify signal at correct molecular weight (~17 kDa)

• For immunofluorescence: Compare staining patterns with published literature

• For flow cytometry: Use positive and negative cell populations

Sigma-Aldrich reports that for their polyclonal antibody (07-441), specificity was confirmed by the ability of 1 μM of the immunizing peptide to completely abolish detection of Histone H3 in western blot analysis of HeLa acid extracts .

How can Di-Methyl-Histone H3 (Lys9) antibodies be incorporated into multi-omics approaches studying chromatin dynamics?

Integrating H3K9me2 profiling with other omics approaches provides powerful insights into chromatin regulation:

Multi-omics Integration Strategies:

• ChIP-seq with RNA-seq: Correlate H3K9me2 distribution with gene expression profiles

• CUT&Tag with ATAC-seq: Compare H3K9me2 localization with chromatin accessibility

• ChIP-seq with Hi-C: Relate H3K9me2 enrichment to 3D chromatin organization

• ChIP-MS with proteomics: Identify proteins associated with H3K9me2-marked chromatin

Analytical Approaches:

• Use computational tools to identify correlations between H3K9me2 and other epigenetic marks

• Apply machine learning algorithms to predict functional outcomes of H3K9me2 patterns

• Develop network models integrating H3K9me2 with other chromatin features

Active Motif offers services combining ChIP-seq with other genomic approaches, including bioinformatic integration . For such integrative approaches, monoclonal antibodies with high specificity like Cell Signaling's D85B4 are recommended for consistency across multiple experimental platforms .

What are the emerging technologies that utilize Di-Methyl-Histone H3 (Lys9) antibodies for single-cell epigenomic profiling?

Single-cell epigenomics is revolutionizing our understanding of cellular heterogeneity:

Emerging Single-Cell Technologies:

• Single-cell CUT&Tag: Maps H3K9me2 in individual cells with higher sensitivity than scChIP-seq

• CITE-seq with histone modifications: Combines surface protein profiling with intracellular H3K9me2 detection

• scNOMe-seq with targeted H3K9me2 enrichment: Integrates nucleosome positioning with H3K9me2 mapping

• Mass cytometry (CyTOF): Enables quantification of H3K9me2 alongside dozens of other cellular markers

Technical Considerations for Single-Cell Applications:

• Use highly specific monoclonal antibodies to minimize background

• Optimize fixation and permeabilization for single-cell suspensions

• Consider barcoding strategies for multiplexed sample processing

• Implement rigorous computational analysis pipelines for sparse data

Active Motif offers Single-Cell Services that can be combined with their validated Di-Methyl-Histone H3 (Lys9) antibodies for cutting-edge epigenomic profiling at single-cell resolution .

How do patterns of H3K9 dimethylation compare across different model organisms, and what are the implications for evolutionary studies?

Comparative analysis of H3K9me2 across species reveals both conservation and divergence:

Cross-Species Patterns:

• H3K9me2 is highly conserved from yeast to humans, suggesting fundamental roles in genome organization

• The specificity of many H3K9me2 antibodies extends across multiple species including human, mouse, rat, and even Drosophila and Schizosaccharomyces pombe

• The enzymes responsible for H3K9 dimethylation show evolutionary conservation but with species-specific adaptations

Evolutionary Implications:

• H3K9me2 plays roles in heterochromatin formation across diverse species

• The distribution and density of H3K9me2 varies between species, potentially reflecting genome architecture differences

• Expansion of H3K9 methyltransferase gene families correlates with genome complexity

Experimental Approaches:

• Use antibodies with validated cross-species reactivity

• Compare ChIP-seq profiles across evolutionary distances

• Integrate with synteny analysis to identify conserved regulatory domains

• Examine H3K9me2 in the context of species-specific repetitive elements

Bio-Rad's Rabbit anti-Human di-methyl-histone H3 (Lys9) antibody shows broad species cross-reactivity based on sequence conservation, making it suitable for evolutionary studies .

What role does Di-Methyl-Histone H3 (Lys9) play in cellular differentiation and development, and how can researchers best study these processes?

H3K9me2 is increasingly recognized as a critical regulator of cellular differentiation:

Developmental Roles:

• Establishment of cell-type-specific gene silencing during lineage commitment

• Formation of facultative heterochromatin domains during differentiation

• Regulation of developmental enhancers and promoters

• Stabilization of cell identity by suppressing alternative lineage genes

Methodological Approaches:

• Time-course ChIP-seq: Profile H3K9me2 dynamics during differentiation

• CUT&Tag in limited cell populations: Map H3K9me2 in rare developmental intermediates

• CRISPR-based recruitment: Targeted recruitment of H3K9 methyltransferases to study causality

• Organoid models: Examine H3K9me2 in complex developmental systems

Technical Recommendations:

• Use highly specific antibodies validated for the model system of interest

• Combine with lineage tracing or reporter systems to identify specific cell populations

• Implement careful normalization strategies when comparing different developmental stages

• Consider chromatin accessibility and other histone modifications in integrated analyses

How are alterations in H3K9 dimethylation patterns implicated in disease states, and what methodological approaches are recommended for clinical samples?

Dysregulation of H3K9me2 is associated with various pathological conditions:

Disease Associations:

• Cancer: Altered H3K9me2 distribution contributes to oncogene activation and tumor suppressor silencing

• Neurodegenerative disorders: Disrupted H3K9me2 patterns in conditions like Alzheimer's and Huntington's

• Cardiovascular disease: Aberrant H3K9me2 in vascular remodeling and cardiac hypertrophy

• Autoimmune disorders: Changes in H3K9me2-mediated silencing of immune-related genes

Clinical Sample Methodologies:

• FFPE-compatible ChIP: Modified protocols for formalin-fixed paraffin-embedded tissues

• CUT&Tag for limited biopsies: Effective with as few as 1,000-50,000 cells

• Tissue microarrays: Immunohistochemical analysis of H3K9me2 across multiple samples

• Liquid biopsies: Analysis of circulating nucleosomes with H3K9me2 modifications

Recommendations for Clinical Applications:

• Standardize sample collection and processing protocols

• Include normal adjacent tissue controls

• Use cell-type-specific markers to account for cellular heterogeneity

• Apply batch correction methods to minimize technical variation

• Consider monoclonal antibodies for improved reproducibility across clinical cohorts

What computational approaches are recommended for analyzing genome-wide H3K9me2 distribution patterns from ChIP-seq or CUT&Tag experiments?

Computational analysis of H3K9me2 data presents unique challenges:

Analytical Challenges:

• Broad domains of enrichment rather than sharp peaks

• Enrichment in repetitive regions of the genome

• Integration with other epigenomic and transcriptomic data

• Normalization across different experimental conditions

Recommended Computational Pipelines:

• Domain calling: Use algorithms designed for broad histone marks (e.g., SICER, diffreps, histoneHMM)

• Signal normalization: Apply appropriate normalization methods (spike-in, total H3, input controls)

• Integration tools: Implement multi-omics integration frameworks (e.g., ChromHMM, Segway)

• Visualization approaches: Utilize genome browsers with capabilities for displaying broad domains

Advanced Analysis Strategies:

• Develop custom pipelines for detecting dynamic changes in domain boundaries

• Apply machine learning approaches to classify chromatin states

• Implement network analysis to identify coordinated regulatory modules

• Use 3D genome data to contextualize H3K9me2 domains in spatial chromatin organization

Active Motif and other companies offer bioinformatic services specifically designed for histone modification data analysis, including tools optimized for broad marks like H3K9me2 .